Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
President Trump Drops 10B IRS Lawsuit as DOJ Creates 18B Lawfare Compensation Fund Assessing Retirement Readiness Can 46 Million Support an Early Retirement at Age 55 Disneys The Mandalorian and Grogu Opens to LowestEver Star Wars Box Office at 82 Million NatWest Group Receives Analyst Upgrade from BNP Paribas Signals Growing Confidence Advent and ADIABacked Innio Targets 203 Billion Valuation in US IPO Astrotech Corporation ASTC Q1 2024 Earnings Net Loss Deepens as Company Focuses on Technology Commercialization uCloudlink Group Inc Q1 2026 Earnings EPS Beats Estimates Amid Cost Discipline OLED Q1 2026 Earnings EPS Misses Estimates by Wide Margin But Stock Climbs Datavault AI Inc DVLT Q1 2026 Earnings Widerthanexpected loss drags shares lower OVLY Q3 2023 Earnings EPS of 089 Reflects Steady Performance Amid Challenging Rate Environment 51Talk COE Holds Steady Near Support Consolidation Phase in Focus VS Media Holdings VSME Surges 29 Testing Key Resistance at 110 DTE Energy Debenture DTK Holds Steady Near 2478 Amid FixedIncome Stability Emerson Electric EMR Gains Ground Testing Resistance at 14324 Germany Pursues Stronger China Ties as EU Divisions Widen Over Trade Policy Singapore Stocks Close Modestly Higher Amid Middle East Uncertainty STI Rises 04 UK Exports to US Plunge 25 After Trumps Liberation Day Tariffs Leading to Trade Deficit Cryptocurrency Market Reacts to USIran Tensions Bitcoin and Ethereum Flat XRP and Dogecoin Decline RILYL Q1 2024 Earnings Net Loss Reported Preferred Stock Price Edges Higher Digimarc Q1 2026 Earnings EPS Surpasses Estimates Despite Stock Decline GPCR Q1 2026 Earnings Smaller Loss Than Expected as Pipeline Advances Mercury General Corporation Q1 2026 Earnings Strong Earnings Beat Driven by Underwriting Discipline Eupraxia Pharmaceuticals EPRX Q1 2026 Earnings Clinical Progress Overshadows Slight EPS Miss C4 Therapeutics CCCC Q1 2026 Earnings Narrowing Losses Drive Surprise Beat Despite Zero Revenue